A strong bearish view is held on InMune Bio (INMB) following the failure of its Phase 2 Alzheimer's drug trial to meet its primary goal. The analyst is short the stock, believing it could fall below $1 per share and that the company's positive spin on subgroup data is misleading. Conversely, Sarepta Therapeutics (SRPT) is presented as a long-term value investment for patient investors. While considered a "good value play," the investment in SRPT is expected to be a "slog" and may take time to materialize. Therefore, SRPT should only be considered as one component within a larger, diversified portfolio.

InMune Bio (INMB)

• The primary discussion revolves around InMune Bio's Phase 2 "mindful" trial for its Alzheimer's drug, X-Pro.
• Bearish Sentiment: The speaker is extremely bearish on the stock and holds a short position. He believes the stock price will fall significantly, potentially "below one" dollar.
• Trial Results:
  • The trial failed to meet its primary cognitive endpoint in the main patient group (the modified intent-to-treat population). The speaker states this was an expected failure.
  • The company is highlighting a "predefined" subgroup analysis of patients with two or more biomarkers of inflammation, where they claim to have observed a cognitive benefit.
  • The speaker dismisses this subgroup analysis as misleading and potentially fraudulent, a common tactic used to spin negative trial results. He notes there are typos in the official press release, which he views as a sign of incompetence.
• Company Actions:
  • InMune plans to submit for "breakthrough designation" with the FDA based on the subgroup data.
  • The company will present more data at the AAIC conference in July and plans to meet with the FDA before the end of the year.
• Market Reaction:
  • Prior to the official news, there was confusion among some investors about a "fake" presentation, which the speaker dismisses.
  • The speaker refers to long-term investors as "bag holders" and advises them to sell and accept their losses, stating they are "lucky to get $2."

Takeaways

• Extreme High Risk: The failure to meet the primary endpoint is a significant negative catalyst for INMB. The company's future is highly uncertain and depends on convincing the FDA and potential partners that the subgroup analysis is meaningful, which is a very difficult task.
• Be Skeptical of Subgroup Analysis: Investors should be extremely cautious when a company's primary trial endpoint fails, and they pivot to highlighting positive results in a small subgroup of patients. This is often a red flag and rarely leads to drug approval without further, successful trials.
• Bearish Outlook: The speaker's strong conviction and short position indicate a belief that the stock has much further to fall. The commentary suggests that any positive spin from the company should be viewed with a high degree of skepticism.

Sarepta Therapeutics (SRPT)

• Bullish Sentiment: The speaker mentions that he is "long, Sarepta", indicating a bullish view and that he owns the stock.
• Investment Thesis: He describes SRPT as a "good value play".
• Timeline & Risk: The investment is characterized as a "slog," which implies that it may take a long time to play out and could experience volatility along the way. He explicitly advises that it "shouldn't be the only stock in your portfolio," highlighting the need for diversification.

Takeaways

• Long-Term Bullish Idea: SRPT is presented as a potential long-term investment for investors who see value in the company.
• Patience Required: The term "slog" suggests investors should not expect quick, easy gains. This is a position that may require holding through periods of little movement or downturns.
• Diversification is Key: As with any single stock, especially in the volatile biotech sector, it's important not to be over-concentrated. This stock could be considered as one part of a larger, diversified portfolio.

"Capper" (Ticker Unknown)

• Bearish Sentiment: The speaker is very bearish on this stock, stating, "capper is a short I like the capper short a lot."
• Difficulty to Short: This is not an easy trade for the average investor. The speaker notes that the stock is "hard to borrow on Schwab" and has a very high borrow rate of 50%.

Takeaways

• A Short Idea for Professionals: While the speaker is bearish, the practicalities of shorting this stock make it an unfeasible idea for most retail investors.
• High Cost of Shorting: A 50% borrow rate means an investor would have to pay 50% of the position's value annually just to maintain the short. This high cost can quickly erase any potential profits from a decline in the stock price. This is generally a signal of a "crowded" short trade.